Access Industries Reveals 6.02% Stake in Newly Merged Yarrow Bioscience
Summary
Access Industries affiliate AI Biotechnology LLC holds a 6.02% stake in Yarrow Bioscience after the reverse merger and reverse stock split, with 22,331 shares and warrants for 155,849 shares.
Key Events · Ownership and Investor Activity · VYNE
-
6.02% Stake Disclosed
AI Biotechnology LLC, controlled by Len Blavatnik's Access Industries, reports beneficial ownership of 22,331 shares and warrants to purchase 155,849 shares, representing 6.02% of Yarrow Bioscience's post-merger outstanding shares.
-
Post-Merger Ownership Revealed
The stake results from the reverse merger and 1-for-50 reverse stock split, which converted AI Biotechnology's pre-split holdings of 1,116,585 shares into 22,331 shares and adjusted its warrants from 7,792,448 to 155,849 shares.
-
Institutional Backing Confirmed
The filing confirms continued support from a major institutional investor following the merger, with the stake valued at approximately $5.1 million based on today's stock price of $28.56.
-
Merger and Split Context
The merger closed on July 27, 2026, and the reverse stock split became effective July 24, 2026, with the combined company now operating as Yarrow Bioscience, Inc. and trading under the ticker YARW.
Analysis · VYNE · Life Sciences
Following the reverse merger and a 1-for-50 reverse stock split, AI Biotechnology LLC—an affiliate of Len Blavatnik's Access Industries—reports holding 22,331 shares and warrants for 155,849 shares of Yarrow Bioscience. That 6.02% stake, worth roughly $5.1 million at today's price, signals continued institutional backing from a major investor as the combined company begins trading under its new structure. The filing offers the first detailed look at a significant holder's position after the complex corporate actions, providing transparency into the post-merger ownership landscape.
At the time of this filing, VYNE was trading at $28.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.